Quantcast

Latest Aromatase inhibitor Stories

2008-07-15 12:01:01

Amgen has reported positive results from a three-year pivotal Phase III placebo-controlled trial evaluating denosumab in the treatment of bone loss in men undergoing androgen deprivation therapy for non-metastatic prostate cancer. In this study of more than 1,400 men, denosumab treatment produced statistically significantly greater increases in bone mineral density (BMD) at the lumbar spine (primary endpoint) and non-vertebral sites compared with placebo at multiple time points. These...

2008-06-16 09:00:10

SAN FRANCISCO and EMERYVILLE, Calif., June 16 /PRNewswire-FirstCall/ -- Bionovo Inc. today announced results from animal studies of its drug candidate, VG101. The data were presented at the Endocrine Society's 90th Annual Meeting in San Francisco, and showed that in animal models, VG101, an estrogen receptor beta selective modulator, is safe and effective for the treatment of vaginal atrophy or "vaginal dryness." "Vaginal dryness occurs in over 50% of menopausal women, resulting in long...

7d95f8c1c092d55b0643de520cc78f7d
2008-03-06 08:15:00

PHILADELPHIA "“ Women whose breast cancer came back after treatment had almost twice as much estrogen in their blood than did women who remained cancer-free "“ despite treatment with anti-estrogen drugs in a majority of the women "“ according to researchers in a study published in the March issue of Cancer Epidemiology, Biomarkers and Prevention, a journal of the American Association for Cancer Research. The findings suggest that high levels of estrogen contribute to an...

2006-06-15 11:25:00

By Amy Norton NEW YORK (Reuters Health) - Being overweight in young adulthood or later in life may raise a woman's risk of ovarian cancer, particularly if she's never had children, researchers have found. In a study of 2,110 women with and without ovarian cancer, researchers found that those who were relatively heavy, either in recent years or at the age of 18, were more likely than thinner women to develop the disease. But the relationship between weight and ovarian cancer was strongest...

2006-04-18 11:30:00

By Maggie Fox, Health and Science Correspondent WASHINGTON (Reuters) - The osteoporosis drug Evista works as well as tamoxifen in reducing the risk of breast cancer in high-risk older women, with fewer dangerous side effects, researchers said on Monday. Both drugs reduce the risk of breast cancer in high-risk women past menopause by about 50 percent, the researchers said. And the results of the 19,000-woman trial show that Eli Lilly and Co's Evista, known generically as raloxifene, is less...

2005-10-18 08:39:31

By Martha Kerr NEW YORK (Reuters Health) - Chemotherapy with drugs called aromatase inhibitors is unnecessary after lumpectomy, radiation and 5 years of tamoxifen for the vast majority of women with breast cancer, researchers reported at the annual meeting of the American Society for Therapeutic Radiation and Oncology in Denver. Principal researcher Dr. Gary Freedman, of Fox Chase Cancer Center in Philadelphia, presented results of a study of 471 women diagnosed with breast cancer....

2005-09-09 18:22:55

CHAMPAIGN, Ill. -- Why do estrogen-dependent breast-cancer cells grow and spread rapidly? Researchers at the University of Illinois at Urbana-Champaign say it may be because estrogen virtually eliminates levels of a vitally important regulatory protein. In a paper that will appear in the Sept. 13 issue of the Proceedings of the National Academy of Sciences, the scientists report that human breast-cancer cells exposed to estrogen in their laboratory showed a dramatic reduction in numbers of a...

2005-08-10 00:33:57

MONTREAL  August 10, 2005 - Scientists at the MUHC have made an important discovery that will advance our understanding of how the female hormone estrogen causes growth of breast cancer cells. The research, in collaboration with scientists at the Institut de Recherches Cliniques de Montreal (IRCM) identifies 153 genes that respond to estrogen and one in particular that can be used to halt the growth of breast cancer cells. The study, published in today's Proceedings of the National...

2005-06-06 00:00:00

High-risk breast cancer patients do not appear to have a higher risk of relapse than the general breast cancer population during the first two years after diagnosis, unless their cancer has spread to more than 10 axillary lymph nodes, Italian researchers reported today at the 2nd ESMO Scientific & Educational Conference (ESEC) in Budapest, Hungary. Dr. Marina Cazzaniga from Treviglio Hospital, Italy, and colleagues in the NORA study, have been studying 3,500 patients being treated for...

2004-11-30 18:00:11

TUESDAY, Nov. 30 (HealthDayNews) -- If you're taking raloxifene (Evista) because you have osteoporosis, a new study finds a probable added benefit: The drug may also significantly reduce your risk of developing breast cancer. The study, which appears in the Dec. 1 issue of the Journal of the National Cancer Institute, found that women taking raloxifene for eight years had a 59 percent lower risk of invasive breast cancer and a 66 percent lower risk of developing estrogen-receptor positive...


Word of the Day
Cthulhu
  • A gigantic fictional humanoid alien god being described with a head resembling an octopus and dragon wings and claws, around whom an insane cult developed.
  • Pertaining to the mythos of Cthulhu and additional otherworldly beings created by H. P. Lovecraft or inspired by his writings and imitators.
This word was invented in 1926 by H.P. Lovecraft for his short story, 'The Call of Cthulhu.' 'Cthulhu' may be based on the word 'chthonic,' which in Greek mythology refers to the underworld.
Related